Login / Signup

Targeting CCL24 in Inflammatory and Fibrotic Diseases: Rationale and Results from Three CM-101 Phase 1 Studies.

Adi MorScott FriedmanSharon HashmueliAmnon PeledMassimo PinzaniMatthew FrankelRifaat Safadi
Published in: Drug safety (2024)
NCT06025851, NCT06037577, and NCT06044467. Date of registration: September 2023.
Keyphrases
  • oxidative stress
  • clinical trial
  • idiopathic pulmonary fibrosis
  • cancer therapy
  • liver injury
  • liver fibrosis
  • case control
  • drug induced